We are live on ! Find out more

CRISPR Therapeutics

CRSP

Market cap $5.23B

54.11 USD

+2.64

5.13%

At close Updated Oct 28, 4:00 PM EDT

Pre-market

After hours

53.58

-0.53

0.98%

1 day

5.13%

5 days

7.92%

1 month

0.04%

3 months

13.8%

6 months

3.94%

Year to date

0.63%

1 year

-15.68%

5 years

-42.44%

10 years

223.24%

About: Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Employees: 393

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 57.1%

Neutral 34.7%

Negative 8.2%

The Motley Fool

Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More

One of CRISPR Therapeutics' leading pipeline candidates, CTX310, arguably has a larger market opportunity than Casgevy. The biotech could make significant clinical progress with this and other medicines over the next five years.

Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More

Zacks Investment Research

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $49.39, marking a -1.2% move from the previous day.

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

Zacks Investment Research

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

Zacks Investment Research

Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet

CRISPR Therapeutics Announces Chief Financial Officer Transition

ZUG, Switzerland and BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that its Chief Financial Officer, Raju Prasad, Ph.D., will be stepping down from the Company to pursue external opportunities, and A.J.

CRISPR Therapeutics Announces Chief Financial Officer Transition

The Motley Fool

Where Will CRISPR Therapeutics Stock Be in 2030?

CRISPR Therapeutics has an approved product on the market that could gain significant commercial traction over the medium term. The company could also make substantial pipeline and regulatory progress.

Where Will CRISPR Therapeutics Stock Be in 2030?

The Motley Fool

Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.

CRISPR Therapeutics' shares have declined more than 25% over the past year. The gene-editing biotech has one approved therapy, Casgevy.

Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.

Zacks Investment Research

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $49.21, signifying a -4.48% move from its prior day's close.

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

Zacks Investment Research

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

CRISPR Therapeutics AG (CRSP) closed at $51.55 in the latest trading session, marking a -3.45% move from the prior day.

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

Zacks Investment Research

Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock

See News Rankings

Price charts implemented using Lightweight Charts™